[Bleedings during vitamin K antagonist therapy associated with ciclosporin and rifampicin].
Laurent
L
Chouchana
Eva
E
Languille
Nicolas
N
Weiss
Eliane M
EM
Billaud
Agnès
A
Lillo-Le Louet
D000368:Aged; D000925:Anticoagulants / Q000009:adverse effects* / Q000627:therapeutic use; D000995:Antitubercular Agents / Q000008:administration & dosage / Q000009:adverse effects*; D015897:Comorbidity; D016572:Cyclosporine / Q000008:administration & dosage / Q000009:adverse effects*; D057915:Drug Substitution; D004359:Drug Therapy, Combination; D005260:Female; D006470:Hemorrhage / Q000139:chemically induced* / Q000188:drug therapy; D006493:Heparin / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage / Q000009:adverse effects*; D016030:Kidney Transplantation; D017563:Lung Diseases, Interstitial / Q000139:chemically induced; D010493:Pericarditis / Q000139:chemically induced; D010630:Phenindione / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D019338:Polypharmacy; D011183:Postoperative Complications / Q000139:chemically induced* / Q000188:drug therapy; D012293:Rifampin / Q000009:adverse effects*; D020123:Sirolimus / Q000009:adverse effects; D020246:Venous Thrombosis / Q000188:drug therapy; D014812:Vitamin K / Q000037:antagonists & inhibitors* / Q000627:therapeutic use
D000925:Anticoagulants; D000995:Antitubercular Agents; D007166:Immunosuppressive Agents; D014812:Vitamin K; D010630:Phenindione; D016572:Cyclosporine; D006493:Heparin; C017673:fluindione; D012293:Rifampin; D020123:Sirolimus